



Published in final edited form as:

*J Biol Chem.* 2016 October ; 21(9): 897–911. doi:10.1177/1087057116660277.

## High-throughput platform for identifying molecular factors involved in phenotypic stabilization of primary human hepatocytes *in vitro*

Jing Shan<sup>a</sup>, David J. Logan<sup>b</sup>, David E. Root<sup>b</sup>, Anne E. Carpenter<sup>b</sup>, and Sangeeta N. Bhatia<sup>a,b,c,d,e,f,g</sup>

<sup>a</sup>Harvard–MIT Division of Health Sciences and Technology, MIT E25-518, 77 Massachusetts Ave, Cambridge, MA 02139

<sup>b</sup>The Broad Institute of MIT and Harvard 415 Main Street, Cambridge, MA 02142

<sup>c</sup>Department of Medicine, Brigham and Women's Hospital 75 Francis St, Boston, MA 02115

<sup>d</sup>Institute for Medical Engineering and Science, MIT E25-330, 77 Massachusetts Ave, Cambridge, MA 02139

<sup>e</sup>Department of Electrical Engineering and Computer Science, MIT 38-401, 77 Massachusetts Ave, Cambridge, MA 02139

<sup>f</sup>David H. Koch Institute for Integrative Cancer Research, MIT 76-158, 77 Massachusetts Avenue, Cambridge, MA 02139

<sup>g</sup>Howard Hughes Medical Institute 4000 Jones Bridge Road, Chevy Chase, MD 20815-6789

### Abstract

Liver disease is a leading cause of morbidity worldwide and treatment options are limited, with organ transplantation being the only form of definitive management. Cell-based therapies have long held promise as alternatives to whole-organ transplantation, but have been hindered by the rapid loss of liver-specific functions over a period of days in cultured hepatocytes. Hypothesis-driven studies have identified a handful of factors that modulate hepatocyte functions *in vitro* but our understanding of the mechanisms involved remains incomplete. We thus report here the development a high-throughput platform to enable systematic interrogation of liver biology *in vitro*. The platform is currently configured to enable genetic knock down screens and includes an ELISA-based functional assay to quantify albumin output as a surrogate marker for hepatocyte synthetic functions as well as an image-based viability assay that counts hepatocyte nuclei. Using this platform, we identified 12 gene products that may be important for hepatocyte viability and/or liver identity *in vitro*. These results represent important first steps in the elucidation of mechanisms instrumental to the phenotypic maintenance of hepatocytes *in vitro*, and we hope that the tools reported here will empower additional studies in various fields of liver research.

## Keywords

High content screening; Image analysis; Cell-based assays; RNA interference; Hepatocytes

---

## INTRODUCTION

Liver disease is a major healthcare burden with limited treatment options short of organ transplantation. Cell-based therapies represent promising alternatives, particularly for organs with complex repertoires of biochemical functions such as the liver. Progress in the field, however, has been hindered by the propensity of hepatocytes to lose phenotypic functions *in vitro*<sup>1</sup>, and consequently, the lack of a reliable *in vitro* model of human hepatocyte biology capable of predicting clinical outcome. The underlying mechanisms of this cellular decline are not well understood but it is likely that the transformation is related to the loss of the native microenvironment.

*In vivo*, hepatocytes exist within the complex architecture of the liver and interact with diverse extracellular matrix molecules, non-parenchymal cells, and soluble factors. Heterotypic interactions between parenchymal cells (hepatocytes) and their stromal neighbors are known to be important during development<sup>2</sup> and in the adult liver, under both physiologic and pathologic conditions<sup>3,4</sup>. Conventional tissue cultures of primary cells lack such multi-faceted cellular stimuli. Liver microsomes are currently used in high-throughput identification of detoxification enzymes, but their lack of cytoarchitecture and functional cellular machinery including dynamic gene expression systems limits their use in the study of many aspects of liver biology. Liver slices do contain intact cells, but have extremely limited viability (~1 day) and are not readily adapted to high throughput screening. Similarly, hepatic spheroids, and models that manipulate the extracellular matrix (ECM) microenvironment of hepatocytes with Matrigel and/or collagen require a high degree of hepatocyte confluency for long-term survival, and are difficult to miniaturize into a standard and high-throughput format.

*In vitro*, the viability and liver-specific functions of hepatocytes from multiple species can be maintained for several weeks upon co-cultivation with stromal cell types. This co-culture effect can be observed using a wide variety of non-parenchymal cells, both primary and immortalized, from intra-hepatic and extra-hepatic sources, and can be observed even across species barriers<sup>5-7</sup>. Hepatocytes in co-cultures, particularly with murine embryonic J2-3T3 fibroblasts, maintain for weeks the distinct nuclei, polygonal morphology, well-demarcated cell-cell borders, and visible bile canaliculi network displayed by cells *in vivo*. Co-cultures have been utilized to investigate various physiologic and pathologic processes, and more recently, to develop *in vitro* liver models for pharmaceutical drug screening, disease modeling (e.g. HCV, HBV, malaria) and engineered hepatic tissues<sup>8-12</sup>.

In order to better understand the molecular mechanisms driving the phenotypic maintenance of hepatocytes by co-cultures, previous work characterized the type and duration of heterotypic cell-cell interactions required to mediate the co-culture effect. Studies suggest that cell-cell contact between primary hepatocytes and non-parenchymal cells (such as murine embryonic 3T3 fibroblasts) is required for ~18-24 hours, after which continuous

stimulation with stromal-derived soluble signals alone over a distance of <400um is sufficient<sup>13</sup>. These critical soluble factors appear to be constitutively expressed by 3T3 fibroblasts, independent of hepatocyte interactions, and are not involved in any reciprocal signaling loops between hepatocytes and the supporting non-parenchymal cells. A handful of stromal-derived molecules have been implicated in this process. These include liver regulating protein (LRP), E-cadherin, TGF-beta1, and decorin<sup>14-17</sup>. While these molecules have been shown to modulate hepatocyte functions *in vitro*, none of them are sufficient in replacing the stromal cells nor are they all expressed by all cell types known to maintain the hepatocyte phenotype. Using a gene expression profiling approach, we had previously identified additional candidate fibroblast genes that may play a role in stabilization of liver-specific functions<sup>17</sup>. Although these findings are promising, a complete picture of the mechanisms underlying the stabilizing effect of fibroblasts remains elusive. This includes the unknown identity of a single factor or cocktail of factors that can adequately support hepatocytes in culture, emphasizing the need to apply objective, genome-wide approaches to these studies.

We thus report here the development of a high-throughput genetic screening platform (Fig. 1A) in order to identify the most critical stromal cell gene products involved in the stabilization of phenotypic functions of primary human hepatocytes (Fig. 1B). We hope our findings will provide a foundation for a more complete understanding of liver phenotype maintenance, with implications for basic research, drug development, molecular therapeutics, and cell-based therapies.

## MATERIALS and METHODS

### Cell Culture

**J2-3T3 Culture.**—Passage 2 J2-3T3 murine fibroblasts were obtained from Howard Green (Harvard) and kept in liquid nitrogen until use. Cells were maintained under standard tissue culture conditions, in 1X DMEM media containing 10% BS and 1% Penicillin-streptomycin. Fibroblasts were grown in T-150 tissue culture flasks and passaged 1:10 using 0.25% Trypsin-EDTA when cells reached confluency. Experiments used J2-3T3s ranging in passage numbers from P7 to P9.

**Hepatocyte Culture.**—Primary human hepatocytes were purchased in cryopreserved suspension from Celsis In vitro Technologies, and kept in liquid nitrogen until use. To thaw, cells were pelleted by centrifugation at 50g for 10 min. The supernatant was discarded before resuspension of cells in hepatocyte culture medium, which consisted of 1X DMEM supplemented with 10% fetal bovine serum (FBS), 15.6 ug/ml insulin, 7.5 ug/ml hydrocortisone, 16 ng/ml glucagon and 1% penicillin-streptomycin.

**Automated Cell Seeding.**—Cell suspensions were diluted to the desired densities and kept in suspension using a magnetic stir bar. A Thermo Combi robot was used to dispense cells into 384-well formats using speed setting low and standard cassette, 30ul/well.

## Functional Assays

**Albumin Competitive ELISA.**—A saturating amount of human albumin (40 $\mu$ l/well of 50 $\mu$ g/mL albumin) was coated onto the walls of adsorptive 384-well plates (NUNC MaxiSorp plates, cat# NUNC 460372) at room temperature overnight under agitation. 20 $\mu$ l of sample supernatant was then introduced and competed with coated albumin for binding to HRP-conjugated antibodies (MPBio Cat #55235). The amount of bound antibody was then quantified via an ultra-sensitive chemiluminescent substrate (Thermo SuperSignal ELISA Pico Chemiluminescent Substrate, Cat # 37070). The competitive ELISA signal was normalized to the standard deviation of all 44 control wells found on the same plate to yield a z-score. Due to the competitive nature of the ELISA assay, higher ELISA z-scores represent lower albumin output.

**Biochemical Assays.**—Urea concentration was quantified using a colorimetric assay that reacted diacetylmonoxime with acid and heat, following product instructions (Stanbio Labs Urea Nitrogen Test, Ref # 0580-250).

**Cytochrome-P450 Induction.**—7-benzyloxy-4-trifluoromethylcoumarin (BFC, BDGentest) was added to cultures at 50 $\mu$ M and incubated for 1 hr at 37C in phenol-red free media. Many different CYP450 isoforms process BFC into its fluorescent product of 7-hydroxy-4-trifluoromethylcoumarin (7-HFC), which was then quantified fluorometrically.

**Automated Plate Washing.**—Washing for plates containing cells was done manually to prevent cell loss. Plate washing for ELISA was performed on the BioTek ELx-405 HT, using the following optimized settings:

- Prime: Prime\_200 using DI water
- Wash: Named program HEPHELISA
  - Method
    - ◆ Number of cycles = 02
    - ◆ Wash Format = Plate
    - ◆ Soak/Shake = Yes
    - ◆ Soak Duration = 010 sec
    - ◆ Shake before soak = yes
    - ◆ Shake Duration = 005 sec
    - ◆ Shake Intensity = 4 (18 cycles/sec)
    - ◆ Prime after soak = No
  - Disp
    - ◆ Dispense volume = 100 $\mu$ l/well
    - ◆ Dispense flow rate = 05
    - ◆ Dispense height = 120 (15.240 mm)

- ◆ Horizontal X disp pos = 25 (1.143mm)
- ◆ Horizontal Y disp pos = 20 (0.914mm)
- ◆ Bottom wash 1<sup>st</sup> = no
- ◆ Prime before start = no
- Aspir
  - ◆ Aspir. Height = 020 (2.540 mm)
  - ◆ Horiz. X Asp. Pos = 00
  - ◆ Horiz Y asp pos = 00
  - ◆ Asp rate = 05 (6.4 mm/sec)
  - ◆ Asp delay = 0000 msec
  - ◆ Cross-wise aspir = yes
  - ◆ Cross-wise on = all
  - ◆ Cross-wise height = 020 (2.540mm)
  - ◆ Cross-wise X horiz. Pos = 00
  - ◆ Cross-wise Y horiz. Pos = 00
  - ◆ Final asp = Yes
  - ◆ Final asp. Delay = 0000 msec

**Automated Plate Reading.**—A Perkin Elmer Envision 2102 Multilabel Reader was used to quantify ELISA signal, integrated over 0.1 sec using luminescence 700 emission filter and measurement height of 6.5mm.

#### **Fibroblast Viability Assay (AlamarBlue)**

Plated J2-3T3 fibroblasts were incubated with the AlamarBlue (Thermo) reagent following manufacturer protocols. Stock solution was diluted 10x in culture medium and incubated with seeded J2-3T3 fibroblasts for 1hr at 37C. The level of fluorescence was then read using an excitation wavelength of 540–570 nm (peak excitation is 570 nm) and emission wavelength of 580–610 nm (peak emission is 585 nm). It is important that all reagents and media are pre-warmed to 37C prior to addition to cells; failure to do so leads to significant edge effects.

#### **Hepatocyte Viability Assay (Imaging)**

**Image Acquisition.**—Cultures of hepatocytes and J2-3T3 fibroblasts were fixed using 4% paraformaldehyde (PFA) in black-walled, clear- and flat-bottomed 384-well plates (Corning). Fixed samples were then stained with Hoechst 33342. It is important to note that the cell membrane is much more permeable to Hoechst 33342 than Hoechst 33258; thus an additional permeabilization step using 0.1% Triton-X for 30 min is necessary if visualizing nuclei with Hoechst 33258. Images of fluorescently labeled nuclei were acquired and

digitized using a high-throughput screening microscope (Molecular Devices IXM) coupled to a barcode reader and robotic arm (Thermo) for automated plate loading. The microscope was configured to self-focus, first using lasers to identify the bottom of wells via differences in the refractive index of plastic and fluids, then using image-based focusing algorithms that scan through a z-stack of ~200  $\mu\text{m}$  in ~50 $\mu\text{m}$  steps in search of the plane with the sharpest images. Accurate examination of nuclear morphology required image acquisition with a 20x objective. 50% of the well area was sampled in a checkerboard fashion, imaging a total of 21 sites per well in order to balance burden of analysis with potential sampling errors.

**Image Processing and Nuclei Identification.**—We used the freely available open-source software CellProfiler for all image analysis<sup>18</sup>, and the configured image analysis pipelines are provided online ([http://cellprofiler.org/published\\_pipelines.html](http://cellprofiler.org/published_pipelines.html)). All images (Figure 2A) underwent illumination correction, as the background intensities varied by up to 1.5 fold across a field of view and often caused unacceptable intensity artifacts (Figure 2B). The illumination correction algorithm averaged all acquired images per plate to identify and normalize consistent discrepancies in the staining intensities across the field of view<sup>19</sup>. All corrected images then underwent a custom image analysis pipeline for nuclei identification (segmentation), by smoothing and using relative peaks in intensity to separate overlapping nuclei. For each identified nucleus, we measured a large number of features to construct a nuclear profile, including measures of nuclear size, shape, and texture, and the number of punctate sub-nuclear spots (Figure 2B, bottom). This per-cell data profile was stored in a MySQL database (Oracle, Inc.) and was subsequently used to train supervised machine learning algorithms to automatically classify nuclei as hepatocytes or fibroblasts (Figure 2C).

**Nuclei Classification and Quantification.**—The nuclear profiles generated by CellProfiler were loaded into CellProfiler Analyst<sup>20</sup> for training of supervised machine learning algorithms to distinguish and count hepatocyte nuclei (Figure 2C). Manually created training sets of representative hepatocytes and fibroblasts (50 example objects each) generate a preliminary set of rules for nuclei classification using the GentleBoosting algorithm applied to regression stumps<sup>20</sup>. This rule set was used by CellProfiler Analyst to classify a new batch of nuclei, outputting the results for manual error correction. Iteration of this process refined the rule set until an acceptable accuracy plateau was reached. The final rule set was then applied to the profiles of every nucleus in every image acquired to classify each object as a hepatocyte or fibroblast before outputting a count of each nucleus type per well. The final training set contained 577 objects with an accuracy plateau using a total of 100 rules. We observed that the single feature of nuclear morphology that most effectively distinguished fibroblast nuclei from hepatocyte nuclei was the punctate sub-nuclear structures present in fibroblasts but absent in hepatocytes, due to the murine origin of the former, which is known to have more textured chromatin<sup>26</sup>. The main pipeline, illumination correction pipeline, and the classifier rules are all available at [http://cellprofiler.org/published\\_pipelines.html](http://cellprofiler.org/published_pipelines.html).

## shRNA Library

The custom shRNA library was assembled from The RNAi Consortium (TRC) library, designed and synthesized at the Broad Institute Genetic Perturbation Platform.<sup>24, 25</sup> The pLKO lentiviral delivery vector contains a U6 promoter for constitutive expression of the shRNA sequence, and a PGK promoter to drive PAC conveying puromycin resistance. A total of 44 wells were devoted to control viruses that included 22 distinct pLKO-shRNAs targeting GFP, LacZ, Luciferase, and RFP (32 wells total), a GFP/puro fusion-expressing virus (8 wells), and the pLKO-EmptyT virus that expresses a non-hairpin sequence that therefore does not induce seed-based off-target effects (4 wells).

## Validation Screen

The workflow of the high-throughput screen to validate implicated factors is summarized in Figure 1C. 384-well screening plates (Corning) were incubated with a solution of type-I collagen in water (100 mg/ml, BD Biosciences) for 1 h at 37°C. A feeder layer of J2-3T3 fibroblasts was robotically plated onto the collagen at a density of 4,000 cells/well and allowed to acclimate over 24 hours. Polybrene at 8ug/mL and a library of 362 lentiviruses, of which 318 carried 318 different shRNAs representing the 59 genes of interest as well as 44 wells containing 24 different control vectors, were added to two duplicate plates, centrifuged for 30 min at 37°C, and allowed to incubate for 24 hours prior to selection with 5ug/mL of Puromycin over 2 days. Infection efficiency was calculated as:

## Alamar Blue fluorescence pre-puromycin selection / Alamar Blue fluorescence post selection

In order to avoid donor-to-donor variability, human primary hepatocytes from a single donor were plated onto successfully transduced fibroblasts at a density of 4,000 cells/well and maintained under standard culture conditions with daily replacement of hepatocyte medium for 7 days, during which time the sample plates were kept in metal stacks with uniform air buffers between each plate in order to provide uniform gas and heat exchange. Additionally, breathable membranes and extra water reservoirs were employed to minimize edge effects arising from fluid evaporation. On day 7 of co-culture, culture supernatants were collected for automated ELISA analysis, and cells were fixed in 4% PFA for imaging and analysis, as described under “Functional Assays” and “Hepatocyte Viability Assay”.

## Western Analysis

Samples from transduced J2-3T3 fibroblasts were lysed in RIPA buffer (Upstate Biotechnology, Waltham, MA) with protease inhibitors cocktail (Roche, Indianapolis, IN) and analyzed by Western Blot as previously described<sup>21</sup>. The following primary antibodies were used: Decorin, GAPDH (Cell Signaling, San Jose, CA).

## Statistical Analyses

Assay readiness was assessed via  $Z'$ -factor. The platform and assays were developed to detect two fold changes in hepatocyte populations; therefore, the positive control was set as “2x hepatocytes” or 4000 hepatocytes per well while the negative control was set as “1x hepatocytes” or 2000 hepatocytes per well.

The z-score of each shRNA was calculated as its deviation from the mean of all 44 control wells found on the same plate, normalized to the standard deviation of all control wells on the plate. The control vectors were comprised of 23 distinct shRNAs, which target various reporter genes not found in wild type J2-3T3s to represent the distribution of off-target seed-based effects inherent to shRNAs, plus one GFP-PAC fusion expressing vector and one vector, “EmptyT”, that expresses a short non-hairpin (non-palindromic) sequence to avoid both on- and off-target effects. Hit candidates from the screen were selected according to their z-score, as described under “Hit Selection”. Due to the competitive nature of the ELISA assay, higher ELISA z-scores represent lower albumin output.

## RESULTS

### Liver Platform Development

To best represent normal human physiology in our liver model and to maximize the model’s ability to predict clinical outcome, we opted to employ primary human hepatocytes in our *in vitro* platform. All cells were sourced from a single donor in order to eliminate innate genetic variations that exist within the human population. Eight different donors of cryopreserved human hepatocytes were tested in total. Three were non-plateable, thus incompatible with phenotypic screening. While the remaining five donors all yielded hepatocytes that adhered to rigid collagen in culture, one donor was too young (0.1 years) to exhibit a full repertoire of mature hepatocyte functions while another two donors had poor functions at baseline. Ultimately, we chose donor GHA, a one-year-old Caucasian female who died from dry drowning, whose hepatocytes attached well to rigid collagen and demonstrated good synthetic, detoxification and metabolic functions.

To maintain GHA hepatocytes in culture, we co-cultivated them with murine embryonic J2-3T3 fibroblasts, which we had previously found to be the most effective non-parenchymal cell type at transiently stabilizing hepatocyte phenotype *in vitro*<sup>17</sup>. The platform contained a subconfluent population of hepatocytes on top of a confluent layer of J2-3T3s within 384-well plates (Figure 1A). This design enabled fibroblast-mediated hepatocyte stabilization for at least 9 days and is amenable to genetic manipulation of fibroblast populations in 384-well formats. The number of fibroblasts seeded per well was empirically optimized to 4,000 cells/well in order to establish a confluent feeder layer while minimizing the risk of phenotypic transformations due to overcrowding at the end of a four-day transduction process. The number of hepatocytes seeded per well was empirically optimized to 4,000 cells/well, placing the functional protein output of both control and experimental groups within the linear detection range (Figure 3A). Similarly, the amount of media used per well was empirically optimized to balance opposing needs of oxygen transport and nutrient supply – too much media presented a transport barrier for gas diffusion, causing observable steatosis in cultured hepatocytes; too little media caused nutrient deprivation. In this case, there was an additional instrument-based practical restriction that all fluids handled robotically could only be dispensed in volumes that are multiples of 10 $\mu$ l. All cells were robotically seeded at the lowest possible speed setting in order to minimize shear stresses. During pilot testing, it was observed that fibroblasts had difficulty remaining attached to plain tissue culture plastic



in 384-well formats, thus a matrix coating of Collagen type I was added at a concentration of 100 ug/mL.

### High-throughput Assay Development

To assess cell fates in this platform, we developed three separate high-throughput readouts. The commercially available AlamarBlue assay was employed to quantify viability of the fibroblast feeder layer, prior to initiation of fibroblast-hepatocyte co-cultures. This assay was also used to measure transduction efficiency and enabled optimization of transduction procedures by measuring viability in the absence and presence of puromycin for selection of cells carrying the puor gene that was included in the shRNA viral vector. Two additional assays were developed to measure hepatocyte functions and cell numbers after one week of heterotypic fibroblast-hepatocyte interactions in the aforementioned co-culture setting.

A number of commercial assays exist to measure cell viability in culture, including fluorescent-based live/dead cell stains as well as quantifications of cellular enzyme activity as surrogate markers of cell number. Many of these assays, however, are not amenable to automation due to cumbersome workflow and/or have cytotoxic properties that restrict them to end-point usage only. After testing a number of candidates, including CellTiter-Glo, Ki67 staining and the MTT assay, we chose AlamarBlue to quantify fibroblast viability and transduction efficiency. AlamarBlue is based on the conversion of the molecule resazurin to resorufin through the reducing power of living cells. Resazurin is non-toxic, cell permeable, blue in color and minimally fluorescent while Resorufin produces bright red fluorescence, thus providing both a colorimetric and fluorescent distinction between parent and daughter compounds. AlamarBlue yielded linear relationships between fluorescence and fibroblast cell numbers when tested on J2-3T3 fibroblasts in 384-well formats, with an effective range of 2,000 to 16,000 cells and a coefficient of determination of  $R^2 = 0.98$ . The incubation period was empirically optimized to one hour, though the data shows an acceptable window between one and five hours, during which the assay showed excellent signal to noise ratio, with good reproducibility across wells, plates and batches (Figure 3A). Using the AlamarBlue assay, we automated and optimized lentiviral transduction conditions for delivering shRNAs to J2-3T3 fibroblasts in 384-well formats in order to systematically knock down genetic factors of interest. Parameters examined include polybrene concentration for neutralization of cell surface charges, viral titers needed for effective transduction, as well as the concentration of puromycin required for selection of successfully transduced cells. Our results showed that a higher polybrene concentration of 8ug/mL provided superior transduction than 4ug/mL of polybrene. Similarly, puromycin was tested at a concentration range between 0ug/mL and 8ug/mL, and found to be optimal at 5ug/mL (Figure 3B). Using these transduction parameters, we were able to obtain a median infection efficiency of 79.3% (Figure 3B). Knockdowns of target genes were also confirmed via Western analysis (Figure 3B).

In order to assess hepatocyte phenotype *in vitro*, we equipped the high-throughput liver platform with several functional assays. Due to the diverse repertoire of the 500+ documented and yet unidentified biochemical functions of the liver, there does not exist a single all-inclusive, gold-standard assay for measuring hepatocyte functions. We thus opted

to sample 3 major types of liver functions: 1) albumin output as a surrogate marker for protein synthesis functions of the liver through a competitive ELISA, 2) urea generation as a surrogate marker for amino acid metabolism functions of the liver through a colorimetric assay, 3) cytochrome P450 activity as a surrogate marker for detoxification functions of the liver through an enzyme activity assay. For all 3 assays, we optimized parameters such as reagent type, concentration, and volume to develop them into biochemical assays compatible with high-throughput screening. Validation data demonstrated that these assays can confidently ( $Z' > 0$ ) detect two-fold changes in hepatocyte populations with low variance ( $CV < 20\%$ ) and good reproducibility (Figure 3).

For our validation screen, we chose the ELISA-based albumin quantification as the functional readout because it exhibited the highest  $Z'$  and was of the greatest clinical relevance. The most common form of the ELISA assay is a sandwich ELISA that captures the antigen of interest in between 2 layers of antibodies. This assay is difficult to adapt to high-throughput screening due to a cumbersome protocol, which is difficult to program robotically, thus limiting throughput. Therefore, for our liver platform, we employed a competitive ELISA assay, which reduced the length of the workflow by approximately one third. It is important to note here that the competitive nature of the assay inverts the readout such that a higher ELISA  $Z$  score reflects a lower albumin content. When coupled with the optimized fibroblast and hepatocyte cell numbers as well as transduction procedure, the platform and assays are able to easily identify cultures where hepatocytes have lost their liver-specific synthetic functions (Figure 4A “Empty” red dots; the fibroblasts of these cultures were not treated with any lentivirus but still underwent puromycin selection; they thus effectively became hepatocyte-only cultures that lost viability and phenotype by day 7).

In addition to assessing the functional output of hepatocytes, we developed an image-based proliferation assay that uses nuclear morphology to quantify hepatocyte nuclei numbers in co-culture. This allowed us to measure hepatocyte viability in addition to determining hepatocyte synthetic functions on a per cell basis. When visualized with Hoechst stain, hepatocyte nuclei are more uniform in texture while fibroblast nuclei are punctate (Figure 2A). The assay thus visualizes all cell nuclei in culture using a simple Hoechst stain, specifically identifies hepatocytes based on nuclear morphology, and provides a count of the number of hepatocyte nuclei in culture. Imaging of multiple 384-well plates containing untreated hepatocyte-fibroblast co-cultures showed that the image-based readout can confidently ( $Z' > 0$ ) detect two-fold changes in the number of hepatocyte nuclei, with low variance ( $CV < 15\%$ ) and good reproducibility (Figure 3A, 3B).

## Functional Screening

**Selection of genetic factors for systematic knock down**—A large number of non-parenchymal cell types are known to support the co-culture phenomenon. They differ, however, in the degree of hepatic functions that they are able to induce when co-cultivated with primary hepatocytes. J2-3T3 fibroblasts, for example, are able to induce physiological or even supra-physiological levels of liver-specific functions in co-cultivated hepatocytes, while the closely related NIH-3T3 fibroblasts and the primary mouse embryonic fibroblasts (MEFs) from whence these cell lines were originally derived are much lower inducers of the

co-culture effect. Previously, Khetani et. al. conducted gene expression profiling of these three fibroblast populations using Affymetrix GeneChips<sup>17</sup>. Here, we re-analyzed those data to identify 59 genes whose levels of expression correlated strongly with the induction of hepatocyte functions *in vitro*. Using our high-throughput liver platform together with virally-delivered shRNAs, we tested the effect of loss-of-function perturbation of these genes in fibroblast feeder cells on phenotypes of co-cultured hepatocytes to assess the potential role of these stromal factors in the co-culture phenomenon.

The 59 genes exhibited a minimum of five-fold difference in levels of expression between the high inducer J2-3T3s and low inducer MEFs. We prioritized molecules with known functions in cell-cell communications, such as various cell surface (e.g. Delta-like homolog 1), extracellular matrix (e.g. Decorin) and secreted factors (e.g. VEGF-D, ceruloplasmin) and eliminated genes that were flagged for having poor quality-control data on the Affymetrix GeneChips. We also added factors that have been implicated in the co-culture effect through previous investigations (e.g. T-cadherin)<sup>22</sup>. Among these 59 genes were 31 genes whose differential levels of expression correlated positively with the pattern of hepatocyte induction observed (positive inducers); the remaining 33 factors showed expression patterns that correlated negatively with hepatocyte functions (negative inducers). All 59 genes are listed in Table 1.

**Functional screen and hit selection**—To determine if any of these 59 differentially expressed fibroblast genes play a critical role in the maintenance of hepatocyte phenotype *in vitro*, we conducted knock-down studies in J2-3T3 fibroblasts, targeting each gene through a custom shRNA library, and monitoring effects on co-cultured primary hepatocytes. The library contained 4 to 10 different shRNAs for each gene of interest, a redundancy designed to distinguish the real biological effects of gene knock-down from artifacts such as off-target effects and the disruption of potentially critical cellular functions through the random insertion of lentiviral genes into the host genome. Only genes represented by two or more different shRNAs were included in the screen hit list, though exceptions were made for those with particularly profound effects ( $z$ -score  $> 4$ ). All shRNAs were tested in duplicate along with various controls: “empty” red dots represent cultures whose fibroblast feeder layer was not treated with lentivirus but still underwent puromycin selection; these effectively became hepatocyte-only cultures that lacked fibroblast co-culture support; “control vector” blue dots represent treatments with viruses conferring expression of either shRNA targeting reporter genes not found in wild type J2-3T3s that are meant to assess the range of seed-based RNAi off-target activities, or of a non-hairpin (non-palindromic) sequence that should not produce either on- or off-target RNAi-based effects. The resultant mutant J2-3T3 fibroblasts were then co-cultivated with primary human hepatocytes in the high-throughput liver platform and their ability to induce liver-specific functions was examined via the competitive ELISA-based functional assay (where high Z score indicates low albumin output) and the image-based hepatocyte viability assay.

Individual shRNAs were considered biologically active and selected for further analysis if their effect on the feeder cells was to significantly decrease either total albumin output from the hepatocytes or a hepatocyte-number adjusted albumin level. Population level data was directly measured by the ELISA assay and any shRNA with a  $z$  score greater than 3 was

selected ( $p < 0.001$ ). We would like to re-emphasize here that a higher ELISA z score reflects lower albumin output due to the competitive nature of the ELISA assay. Albumin output was also assessed relative to the albumin versus HepCount trend observed for the control vectors. Regression analyses of cultures treated with control vectors (blue dots, which thus contained wild type fibroblasts) revealed the following relationship between ELISA z scores ( $z_{\text{ELISA}}$ ) and imaging z scores ( $z_{\text{HepCount}}$ ):

$$z_{\text{ELISA}} = (-0.37 \times z_{\text{HepCount}})$$

That is, as expected, albumin levels were higher (lower ELISA z-score) when more hepatocyte numbers were higher (higher HepCount z-score). Applying to this population-adjusted albumin level the same hit selection criteria of z score greater than 3 ( $p < 0.001$ ), hit shRNAs were considered to be those for which  $z_{\text{ELISA}} > (-0.37 \times z_{\text{HepCount}} + 3)$ . Additionally, any shRNA with infection efficiency below 20% was eliminated from analyses. The final hit list was thus generated via the following algorithm:

1. [Infection efficiency >20%] AND
2. [ $z_{\text{ELISA}} > (-0.37 \times z_{\text{HepCount}} + 3)$  OR  $z_{\text{ELISA}} > 3$ ] AND
3. [number of active hairpins per gene > 2 OR  $z_{\text{ELISA}} > 4$ ]

A total of 12 hit genes, listed in Table 2, were nominated by this screen in agreement with previous hypotheses that these molecules play an important role in the maintenance of hepatocyte phenotype *in vitro*. The magnitude and consistency of effect of some representative active shRNAs in the hit list is plotted in Figure 4B.

## DISCUSSION

Sourcing of hepatic cells is a fundamental challenge for many fields of liver research. Many are forced to employ xenogeneic sources such as rodent and porcine hepatocytes, or immortalized human hepatocyte cell lines. Animal hepatocytes are extensively studied and easily obtained, but exhibit numerous species-specific differences in hepatocellular functions ranging from apolipoprotein expression, metabolic regulation of cholesterol, to phase I detoxification enzymes. Human hepatocyte cell lines, while expandable, contain mutations and exhibit an abnormal repertoire of liver functions, limiting their clinical relevance.

Primary human hepatocytes present the best functional output and recent advances in cryopreservation technologies have additionally enabled the storage of entire livers of human hepatocytes, enough to power multiple batches of phenotypic screens. This enables hundreds of thousands of knockdown or overexpression studies on a constant genetic background over a period of several months. We recognize that it would be important to test additional donors and genetic backgrounds and recommend changing donors after the completion of primary screening, such as during various follow-up studies. While extensive previous characterizations have shown that high-quality cryopreserved primary human hepatocytes exhibit phenotypes that approach fresh hepatocytes and are thus very useful for *in vitro* liver studies, our findings here indicate that not all donors are suitable for use in phenotypic screens. Therefore, we propose that empirical characterization of each donor of

cryopreserved primary human hepatocytes is an indispensable first step to their use in liver research.

Maintenance of cryopreserved primary human hepatocytes *in vitro* can be achieved transiently via co-cultivation with a variety of non-parenchymal cells. There exist multiple configurations of co-cultures, with varying degrees of architectural organization. The simplest implementation consists of a co-planar distribution of randomly mixed hepatocytes and J2-3T3 fibroblasts on a matrix of rigid collagen type I. More sophisticated designs use semiconductor-driven microtechnology to organize primary hepatocytes into *in vitro* colonies of empirically optimized island sizes, subsequently surrounded by J2-3T3 fibroblasts (MPCC). All configurations of hepatocyte-J2 co-cultures were found to maintain primary human hepatocyte functions *in vitro* for at least 9 days<sup>12, 23</sup>. Generally, increased architectural organization of cells in culture leads to longer-term stabilization of hepatocyte functions, with MPCC being the most optimal configuration, enabling maintenance of hepatocyte functions *in vitro* for 4-6 weeks. However, such segregation of hepatocyte and fibroblast populations limits the number of hepatocytes that engage in heterotypic cell-cell interactions. Additionally, MPCCs are difficult to miniaturize beyond 96-well platforms and in any case, such prolonged periods of hepatocyte functions are neither necessary nor practical for most whole-cell screens. We thus designed our high-throughput liver platform to assume a feeder layer co-culture configuration, which ensures that every hepatocyte has access to a fibroblast and can participate in heterotypic cell-cell signaling.

Significant efforts were dedicated to the development of an image-based hepatocyte viability assay. The co-existence of two different cell types in each well renders their differentiation challenging. Existing measurements of cellular numbers, such as AlamarBlue, CellTiter-Glo and Live/Dead stains all reflect the joint state of the whole well, which allows behavior of the more populous J2-3T3 fibroblasts to mask the number of hepatocytes in culture. We additionally considered generating stable fluorescent clones of hepatocytes; however the rapid decline in hepatocyte viability *ex vivo* as well as their inability to proliferate *in vitro* renders such lengthy manipulations technically unfeasible. Therefore, we needed to develop a custom readout in order to isolate and quantify the hepatocyte subpopulation. Human hepatocytes in culture can be distinguished from underlying J2-3T3 fibroblasts via a variety of methods, including phase-contrast microscopy, staining for hepatocyte-specific markers, and striking species-specific differences in nuclear morphology. Brightfield images, while easy to acquire, are difficult to quantify, particularly in a high-throughput manner. Immunofluorescent staining of particular antigens, while easy to measure in an automated fashion, are difficult and expensive to execute in 384-well and smaller formats with often unacceptable signal to noise ratios. Therefore, we chose to leverage differences in nuclear morphology. It should be noted that the highly textured nature of fibroblast nuclei rendered their segmentation difficult, often leading to the breakup of a single nucleus into multiple nuclei. Therefore, while the assay does ostensibly report numbers of fibroblast nuclei as well as hepatocyte nuclei, it is optimized for accurate detection of hepatocyte nuclei only. We point to our later work, which yielded an image analysis pipeline for more accurate measurement of the number of fibroblasts in co-culture<sup>26</sup>.

Additionally, we recognize that counting nuclei is not always equivalent to counting cells. Hepatocytes in particular are well known for their ability to assume polyploid states and can sometimes contain 8 or more nuclei. While nuclear proliferation does not always translate into cellular proliferation, cell death is always accompanied by a decrease in nuclei numbers. Therefore, nuclei number is still a viable surrogate marker for cell number, albeit without a strict one-to-one correlation. We note that polyploidy can be detected visually in images in followup analysis of hits.

Analyses of the validation screen focused on finding only positive mediators of co-culture and neglected to examine negative mediators, whose knockdown would enhance hepatocyte functions. This decision was made because J2-3T3 fibroblasts are strong inducers of the coculture effect, often supporting physiological to supra-physiological levels of liver-specific synthetic functions *in vitro*. We thus believe that it would not be rewarding to look for negative mediators in a cell type that is inherently already a high inducer of hepatocyte functions. We also prioritized the search for positive mediators because their gene products have the potential to substitute for non-parenchymal cells and directly advance the development of fibroblast-free tissue-engineered hepatic systems. Although negative mediators are less useful in this regard, studies of such factors can provide insight into the signaling pathways involved in the phenotypic maintenance of hepatocytes *ex vivo* and should be conducted in the future. Such studies might be best suited for knock down studies in non-parenchymal cells known to be low inducers of the co-culture effect, such as primary MEFs.

As a first step to analysis of the functional screen results, we examined the effect of Decorin, a putative positive control, in our screen. Decorin is a chondroitin sulfate-dermatan sulfate proteoglycan that binds to collagen, whose role as a positive mediator of the co-culture effect was not only theoretically predicted by gene expression profiling, but also confirmed via studies that showed up-regulation of hepatic functions *in vitro* when co-cultivated with stromal cells on adsorbed Decorin in a dose-dependent manner<sup>17</sup>. In our screen, two active shRNAs were found to represent Decorin and both showed a decrease in hepatocyte functions upon knock-down, consistent with prior findings. Similar to other top hits of the screen (e.g. H2-K1, which encodes for the K region of a histocompatibility protein with a human ortholog of HLA-A; or *Inhba*, which encodes for a subunit of both activin A and inhibin A, both secreted growth factors involved in a myriad of biological processes including cell cycle regulations), it is not immediately apparent how decorin might be maintaining liver functions or what signaling pathways may be involved. These questions are the subject of ongoing investigations.

We also noted that knockdown of Decorin did not completely remove the rescue effects of co-culture on hepatocyte phenotype, again consistent with prior studies that Decorin alone cannot stabilize hepatocytes *in vitro*. In fact, while knockdown of the hit candidates each had significant effects on hepatocyte functions, the co-culture effect was not consistently abolished in any of the cultures with mutant fibroblasts, as evidenced by significantly higher albumin output when compared with hepatocytes cultured alone, without fibroblast support (Figure 4A). Although it is possible this is related to incomplete knockdown of protein products under our experimental conditions, we suspect that multiple signaling molecules

are involved in the maintenance of hepatocyte phenotype *ex vivo*, and that a cocktail of stromal factors will ultimately be needed to replace non-parenchymal cells in hepatic tissue-engineering applications.

In conclusion, we report here the development of a high-throughput human liver model and attendant automatable assays capable of reflecting human liver physiology *in vitro*. These tools were used to conduct a small genetic knockdown screen of fibroblast-derived factors in order to identify molecules important to the maintenance of hepatocyte functions *in vitro*. Overall, we identified 12 genes as priority candidates for further experimental validation and hope the tools reported here will empower additional studies in the various fields of liver research.

## ACKNOWLEDGEMENTS


We would like to thank the members of the Bhatia Lab especially Dr. Heather Fleming, the Broad Institute Imaging Platform, and the Broad Institute Genetic Perturbation Platform especially Dr. Serena Silver and Dr. Federica Piccioni for helpful guidance throughout. This work was supported by the National Institutes of Health (NIH UH3 EB017103, to SNB) as well as a grant from the National Science Foundation (NSF CAREER DBI 1148823, to AEC). Dr. Bhatia is an HHMI Investigator and Merkin Institute Fellow at the Broad Institute of MIT and Harvard.

## REFERENCES

1. Strain AJ, Ex vivo liver cell morphogenesis: One step nearer to the bioartificial liver? *Hepatology* 1999, 29 (1), 288–290. [PubMed: 9862882]
2. Houssaint E, Differentiation of the mouse hepatic primordium. I. An analysis of tissue interactions in hepatocyte differentiation. *Cell Differentiation* 1980, 9 (5), 269–279. [PubMed: 7438211]
3. Olson Michael J., M. MA, Venkatachalam Manjeri A., Roy Arun K., Hepatocyte cytodifferentiation and cell-to-cell communication. CRC press: Florida, 1990; p 71–92.
4. Michalopoulos GK, Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. *Am J Pathol* 2010, 176 (1), 2–13. [PubMed: 20019184]
5. Corlu A; Ilyin G; Cariou S, et al., The coculture: A system for studying the regulation of liver differentiation/proliferation activity and its control. *Cell Biology and Toxicology* 1997, 13(4-5), 235–242. [PubMed: 9298244]
6. Guguenguillou C; Clement B; Baffet G, et al., Maintenance and Reversibility of Active Albumin Secretion by Adult-Rat Hepatocytes Co-Cultured with Another Liver Epithelial-Cell Type. *Experimental Cell Research* 1983, 143 (1), 47–54. [PubMed: 6825722]
7. Bhatia SN; Balis UJ; Yarmush ML, et al., Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. *Faseb Journal* 1999, 13(14), 1883–1900. [PubMed: 10544172]
8. Khetani SR; Bhatia SN, Microscale culture of human liver cells for drug development. *Nature Biotechnology* 2008, 26, 120–126.
9. Ploss A; Khetani SR; Jones CT, et al., Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. *Proceedings of the National Academy of Sciences of the United States of America* 2010, 107 (7), 3141–3145. [PubMed: 20133632]
10. March S, Ramanan V, Trehan K, Ng S, Galstian A, Gural N, Scull MA, Shlomai A, Mota MM, Fleming HE, Khetani SR, Rice CM, and Bhatia SN, Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens. *Nature Protocols* 2015, 10 (12), 2027–2053. [PubMed: 26584444]
11. Chen AA; Thomas DK; Ong LL, et al., Humanized mice with ectopic artificial liver tissues. *Proceedings of the National Academy of Sciences of the United States of America* 2011, 108 (29), 11842–11847. [PubMed: 21746904]


12. Shan J; Schwartz RE; Logan DJ, et al., High-throughput identification of small molecules for human hepatocyte expansion and iPS differentiation. *Nature Chemical Biology* 2013, 9 (8): 514–520. [PubMed: 23728495]
13. Hui EE; Bhatia SN, Micromechanical control of cell-cell interactions. *Proceedings of the National Academy of Sciences of the United States of America* 2007, 104 (14), 5722–5726. [PubMed: 17389399]
14. Corlu A; kneip B; Lhadi C, et al., A plasma membrane protein is involved in cell contact-mediated regulation of tissue-specific genes in adult hepatocytes. *Journal of Cell Biology* 1991, 115(2), 505–515. [PubMed: 1918151]
15. Brieva TA; Moghe PV, Functional engineering of hepatocytes via heterocellular presentation of a homoadhesive molecule, E-cadherin. *Biotechnol Bioeng* 2001, 76(4), 295–302. [PubMed: 11745156]
16. Chia SM; P.C. L; Yu H, TGF-beta1 regulation in hepatocyte-NIH3T3 co-culture is important for the enhanced hepatocyte function in 3D microenvironment. *Biotechnology and Bioengineering* 2005, 89 (5), 565–573. [PubMed: 15669090]
17. Khetani SR; Szulgit G; Del Rio JA, et al., Exploring interactions between rat hepatocytes and nonparenchymal cells using gene expression profiling. *Hepatology* 2004, 40 (3), 545–554. [PubMed: 15349892]
18. Kametsky L; Jones TR; Fraser A, et al., Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software. *Bioinformatics* 2011, 27 (8), 1179–1180. [PubMed: 21349861]
19. Singh S; Bray MA; Jones TR, et al., Pipeline for illumination correction of images for high-throughput microscopy. *J Microsc* 2014, 256 (3), 231–236. [PubMed: 25228240]
20. Jones TR; Carpenter AE; Lamprecht MR, et al., Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. *Proceedings of the National Academy of Sciences of the United States of America* 2009, 106 (6), 1826–1831. [PubMed: 19188593]
21. March S; Hui EE; Underhill GH, et al., Microenvironmental regulation of the sinusoidal endothelial cell phenotype in vitro. *Hepatology* 2009, 50 (3), 920–928. [PubMed: 19585615]
22. Khetani S; Chen AA; Ranscht B, et al., T-cadherin modulates hepatocyte functions in vitro. *FASEB J* 2008, 22 (11), 3768–3775. [PubMed: 18635739]
23. Khetani S; Bhatia SN, Development and characterization of microscale models of rat and human livers. *Hepatology* 2007, 46, 773A–773A.
24. Root DE; Hacohe N; Hahn WC, et al., Genome-scale loss-of-function screening with a lentiviral RNAi library. *Nature Methods*. 2006, 3 (9), 715–719. [PubMed: 16929317]
25. Moffat J; Gueneberg DA; Yang X, et al., A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. *Cell* 2006, 124 (6), 1283–1298. [PubMed: 16564017]
26. Logan DJ; Shan J; Bhatia SN et al., Quantifying co-cultured cell phenotypes in high-throughput using pixel-based classification. *Methods*. 2016, In Press





**Figure 1. Platform and Screen Design.**

(A) High-throughput liver platform. (B) Selection of candidate stromal factors for high-throughput genetic knockdown screening. (C) Validation screen workflow.



**Figure 2. Image Analysis and Machine Learning Classification Workflow.**

(A) Example microscope field and nuclei types. (B) Image analysis workflow with two pipelines: Illumination correction pipeline and main pipeline to segment nuclei, speckles/spots and measure features. (C) Machine learning workflow to classify nuclei. (D) Histograms of the top two distinguishing features, or rules, in the classifier. The most distinguishing feature is speckles per nucleus, with fibroblast nuclei averaging >6 speckles and hepatocyte nuclei ~1. The next most distinguishing feature is Zernike moment [1,1], one of many coefficients of a Zernike polynomial fit to a binary image of each nucleus, which when combined can reconstruct the shape of the nucleus. Many more rules comprise the classifier to help distinguish the nuclei, which is a benefit of the machine learning approach


here. These rules are available for inspection at [http://cellprofiler.org/published\\_pipelines.html](http://cellprofiler.org/published_pipelines.html).

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



### Figure 3. Platform and Assay Characterization.

(A) Brightfield image of feeder layer coculture of J2-3T3 fibroblasts and cryopreserved primary human hepatocytes. Signal strength and variability of attendant high-throughput assays, shown in ranges relevant for screening – (B) AlamarBlue viability assay, (C) image-based hepatocyte viability assay, (D) albumin competitive ELISA functional assay (higher signal corresponds to lower albumin content), (E) urea colorimetric assay, (F) cytochrome P450 activity assay; for hepatocyte density, 1.0x indicates 2000 hepatocytes per well; 0.5x indicates 1000 hepatocytes per well, 2.0x indicates 4000 hepatocytes per well; 4.0x indicates 8000 hepatocytes per well. (G) Puromycin selection curve post transduction of J2-3T3 fibroblasts with lentiviral shRNA library in high-throughput liver platform; (H) infection efficiency of J2-3T3 fibroblasts with lentiviral library in high-throughput liver platform; (I) protein knock down confirmation via Western analysis. (J) High-throughput assay quality metrics. Z'-factors were calculated for two-fold changes in the hepatocyte population and thus used positive controls of “2x hepatocytes” hepatocytes per well and negative controls of “1x hepatocytes” per well. Error bars represent standard deviation.



**Figure 4. Validation screen.**

(A) Primary screening data and hit selection. Due to the competitive nature of the albumin ELISA, higher ELISA z scores reflect lower albumin output. “Empty” red dots represent cultures whose fibroblast feeder layer was not treated with any lenti-virus but still underwent puromycin selection; these effectively became hepatocyte-only cultures that lacked fibroblast co-culture support; or the 44 “control vector” blue dots, 32 dots represent 22 distinct shRNA vectors targeting various reporter genes not found in wild type J2-3T3s to illustrate any off-target effects ubiquitous to shRNAs, 8 dots represent replicates of a GFP-PAC fusion-expressing vector, and 4 dots represent replicates of a non-hairpin (non-palindromic) expressing pLKO vector. “Experimental” black dots represent 318 shRNA

vectors designed to knock down the 59 genes of interest, with an average of 5.4 shRNAs/gene. Green boxes indicate significantly ( $Z > 3$ ) impaired hepatocyte viability or phenotype on both a population and individual cell level. Final hit selection utilized the following algorithm: 1. [Infection efficiency  $> 20\%$ ] AND 2. [ $z_{\text{ELISA}} > (-0.37 \times z_{\text{HepCount}} + 3)$  OR  $z_{\text{ELISA}} > 3$ ] AND 3. [number of active hairpins per gene  $> 2$  OR  $z_{\text{ELISA}} > 4$ ]. (B) Representative hit candidates.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 1.**

Genes tested in validation screening.

Gene	Protein	Gene Families	Gene ID
Acta1	Actin, alpha 1	Actins	11459
Adm	Adrenomedullin	Endogenous ligands	11535
Ccl9	Chemokine ligand 9	Endogenous ligands	20308
Cd44	CD44 antigen	CD molecules	12505
Cdh13	T-cadherin	Major cadherins	12554
Cdkn1a	Cyclin-dependent kinase inhibitor 1A	Cyclin-dependent kinase inhibitors	12575
Col8a1	procollagen, type VIII, alpha 1	Collagens	12837
Cp	Ceruloplasmin	Multicopper oxidases	12870
Ctgf	Connective tissue growth factor	Matricellular proteins	14219
Cwc22	Functional spliceosome-associated protein B	CWC22	80744
Cyba	Cytochrome B-245, alpha polypeptide	p22phox	13057
Dcn	Decorin	Small leucine-rich repeat proteoglycans	13179
Ddx3y	DEAD Box Helicase 3, Y-linked	DEAD-box helicases, Minor histocompatibility antigens	26900
Dhfr	Dihydrofolate reductase	Dihydrofolate reductase	13361
Dkk3	dickkopf WNT signaling pathway inhibitor 3	dickkopf	50781
Dlk1	Delta-like 1 homolog	EGF-like homeotic	13386
Dpysl3	Dihydropyrimidinase-like 3	DHOase	22240
Dtd1	DtyrosyltRNA deacylase 1	DTD	66044
F2r	Thrombin receptor	G-protein coupled receptor	14062
Fhl1	Four and a half LIM domains 1	Four and a half LIM domains	14199
Figf	Vascular endothelial growth factor D	PDGF/VEGF	14205
Gtf2h1	general transcription factor II H, polypeptide 1 (62kD subunit)	General transcription factors	14884
H2-K1	MHC class I antigen	MHC I antigen	14972
Hmgb1	high mobility group box 1	Canonical high mobility group	15289
Hnrnpa3	Heterogeneous nuclear ribonucleoprotein A3	RNA binding motif containing	229279
Hnrpd1	Heterogeneous nuclear ribonucleoprotein D-like	RNA binding motif containing	50926
Htra1	protease, serine, 11 (Igf binding)	Trypsin	56213
Ifi204	interferon, gamma-inducible protein 16	Pyrin and HIN domain	15951
Ifi2711	interferon, alpha-inducible protein 27-like 1	IFI6/IFI27	52668
Igfbp2	Insulin-like Growth Factor Binding Protein 2	IGFBP	16008
Inhba	activin/inhibin beta A	Endogenous ligands	16323
Irf1	Activating transcription factor 3	Basic leucine zipper proteins	16362
Jup	Junction plakoglobin	Armadillo repeat containing	16480
Lasp1	LIM and SH3 protein 1	LIM / nebulin	16796
Mlf1	Myeloid leukemia factor 1	MLF	17349
Myo1b	Myosin IB	Myosin, class I	17912

Gene	Protein	Gene Families	Gene ID
Ndn	Necdin	MAGE	17984
Pdlim1	PDZ and LIM domain 1	Enigma protein	54132
Pkp2	Plakophilin 2	Armadillo repeat containing	67451
Pold2	Polymerase, delta 2, accessory subunit	DNA-directed polymerases	18972
Pr12c3	Prolactin family 2, subfamily c, member 3	Growth hormone	18812
Prrc1	Proline-rich coiled-coil 1	PRRC1	73137
Ptprf	Protein tyrosin phosphatase, receptor type, F	Fibronectin type III domain containing	19268
Racgap1	Rac GTPase Activating Protein 1	GTPase-activating protein	26934
Rgnef	Rho interacting protein 2/Rho specific exchange factor	Rho guanine nucleotide exchange factor	110596
Rock2	Rho-associated coiled-coil containing protein kinase 2	Pleckstrin homology domain containing	19878
Sec23a	Sec23 Homolog A	SEC23/SEC24	20334
Sfrs3	Serine/Arginine-rich splicing factor 3	RNA binding motif containing	20383
Shc1	src homology 2 domain containing transforming protein 1	SH2 domain containing	20416
Snx10	Sorting nexin 10	Sorting nexins	71982
Sorbs1	Sorbin and SH3 domain containing 1	Sorbs1	20411
Ssb	Sjogren syndrome antigen B	RNA binding motif containing	20823
Tardbp	TAR DNA binding protein	RNA binding motif containing	230908
Timm8a1	translocase of inner mitochondrial membrane 8 homolog a	small Tim	30058
Timp2	TIMP metalloproteinase inhibitor 2	Tissue inhibitor of metalloproteinases	21858
Tpd52	Tumor protein D52	TPD52	21985
Tsnax	Translin-associated factor X	Translin	53424
Ttk	TTK protein kinase	TTK protein kinase	22137
Xlr	Xlinked gene family of Bcell surface antigens	Xlr	22441



**Table 2.**

Hit candidate genes from validation screen.

Tier	Gene	Protein	Description
0	DCN	Decorin	Positive Control
1	H2-K1	MHC class I antigen	Strongest hits from validation screen: <ul style="list-style-type: none"> <li>• Multiple independent hairpins</li> <li>• Good reproducibility</li> <li>• KD effects are consistent within screen and with prior predictions</li> </ul>
	Ttk	TTK protein kinase	
2	Rgnef	Rho interacting protein 2/Rho specific exchange factor	<ul style="list-style-type: none"> <li>• Multiple hairpins</li> <li>• Effects are consistent within screen and with prior predictions</li> </ul>
	Pkp2	Plakophilin 2	
	Mlf1	Myeloid leukemia factor 1	
3	CD44	CD44 antigen	<ul style="list-style-type: none"> <li>• Multiple hairpins</li> <li>• Effects are mostly consistent within screen and with prior prediction</li> </ul>
	Ssb	Sjogren syndrome antigen B	
	Tsnax	Translin-associated factor X	
4	Shc1	src homology 2 domain containing transforming protein 1	<ul style="list-style-type: none"> <li>• Multiple hairpins</li> <li>• Effects are consistent within screen</li> </ul>
	Inhba	Activin/inhibin beta A	
	Srsf3	Serine/Arginine-rich splicing factor 3	
	Rock2	Rho-associated coiled-coil containing protein kinase 2	